ClinicalTrials.gg
Enrolling by invitationNCT07093151COMPETEUpdated Apr 21, 2026

Comparison of Post-Craniotomy Blood Pressure Targets

An interventional study of Target SBP <160mmHg and Target SBP <140 mmHg in Intracranial Hemorrhage, Hypertensive and Craniotomy Tumor Removal Surgery, sponsored by Vanderbilt University Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this pragmatic clinical trial is to learn if a more intensive or more liberal blood pressure target after surgery is more effective in improving patient outcomes for adults undergoing craniotomy for removal of a brain tumor. There is little evidence to help doctors decide the best post-operative blood pressure target for their patients. The main question this study aims to answer is if patients with a post-operative systolic blood pressure target of \<160 mmHg will have a shorter hospital length of stay than those with a blood pressure target of \<140 mmHg, without increasing the rate of post-operative bleeding in the brain.

Read the detailed description

Over 160,000 craniotomies, a type of brain surgery, are performed annually in the United States. High blood pressure is believed to increase the risk of post-operative bleeding in the brain, known as intracranial hemorrhage (ICH). This perceived risk has led many doctors to impose post-operative systolic blood pressure (SBP) limits, with aggressive treatment when SBP rises above the target thresholds. The use of intensive SBP goals often requires antihypertensive medication treatment, occasionally including intravenous (IV) drips. These medical therapies could have several adverse effects related to end-organ function. Additionally, close SBP monitoring with an arterial line and/or treatment with IV antihypertensives often requires intensive care unit (ICU) level of care. 40% of academic medical programs use a goal of SBP\<160mmHg as supported by this limited evidence, while 45% of programs use an even more stringent SBP goal of \<140mmHg.

This study is a single-center, pragmatic, randomized trial comparing the effectiveness of these two standard-of-care post-craniotomy SBP goals in reducing patient hospital length of stay, risk of ICH, and adverse side effects of antihypertensive use. Eligible patients will be randomized to receive an order for a target SBP \<140 mmHg or SBP \<160 mmHg during this period. We hypothesize that a target SBP \<160 mmHg will decrease patient hospital length of stay without increasing the risk of ICH.

02

Conditions studied

  • Intracranial Hemorrhage, Hypertensive
  • Craniotomy Tumor Removal Surgery

Keywords

  • Perioperative Care
  • Post-Craniotomy Emergence Hypertension
03

In context

Intracranial Hemorrhage, Hypertensive

23 studies on the registry are indexed under Intracranial Hemorrhage, Hypertensive; 8 are open to participants now.

This study's planned enrollment of 500 is above the median of 306 across 17 interventional studies indexed under Intracranial Hemorrhage, Hypertensive.

Browse Intracranial Hemorrhage, Hypertensive studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Undergoes craniotomy for resection of an intradural brain tumor scheduled using any of the following Current Procedural Terminology (CPT) codes: 61304, 61305, 61330, 61333, 61510, 61512, 61516, 61518, 61519, 61520, 61521, 61524, 61526, 61530, 61545, 61580, 61581, 61582, 61583, 61584, 61585, 61586, 61590, 61591, 61592, 61595, 61596, 61597, 61598, 61600, 61601, 61605, 61606, 61607, 61608, 61615, 61616

Exclusion criteria

Exclusion Criteria:

  • Declines to consent
  • Attending decisions based on intraoperative findings (i.e. attending physician does not have equipoise that either blood pressure threshold would be acceptable for the post-operative care of the patient).
  • Patient is a prisoner
  • Patient is known to be pregnant
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    Comparator Arm 1: SBP target <160 mmHg

    The neuro-intensive care team will monitor the patient's SBP and treat with antihypertensive medications to achieve an SBP\<160mHg. Selection of the appropriate oral or IV medication is at the discretion of the neuro-ICU team; most frequently used agents clinically include nicardipine, labetalol, and hydralazine. Selection of the appropriate agent is based on other clinical elements including severity of hypertension, heart rate, patients' home medication regimens, and any medication interactions or allergies. The blood pressure goal will be continued throughout the hospitalization. The arterial line will be removed at the discretion of the neurosurgery team, typically on the morning of the first day after surgery.

    Other: Target SBP <160mmHg

  • Active comparator
    Comparator Arm 2: SBP Target <140 mmHg

    The neuro-intensive care team will monitor the patient's SBP and treat with antihypertensive medications to achieve an SBP\<140mHg. Selection of the appropriate oral or IV medication is at the discretion of the neuro-ICU team, as described above for Comparator Arm 1. The blood pressure goal will be maintained until the neurosurgery team chooses to 'liberalize' the blood pressure goal to higher SBP levels. The arterial line will be removed when the blood pressure goal is liberalized, typically on the morning of the first day after surgery.

    Other: Target SBP <140 mmHg

Interventions

  • OtherTarget SBP <160mmHg

    For subjects assigned to the SBP \<160 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<160 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.

  • OtherTarget SBP <140 mmHg

    For subjects assigned to the SBP \<140 mmHg group, an SBP target order will be placed to guide the neuro-intensive care team to treat the patient with antihypertensive medications as needed to achieve an SBP \<140 mmHg. Selection of the antihypertensive medication and administration route is at the discretion of the treating team. Patients will undergo regular and frequent blood pressure measurements using the arterial line placed during surgery, or through a non-invasive blood pressure measurement method if no arterial line is present.

06

What researchers measure

Primary outcomes

  1. Hospital length of stay

    Length of patient hospital stay in days

    Time frame: From enrollment to first hospital discharge or 90 days, whichever is sooner

Secondary outcomes

  1. ICU length of stay

    Length of patient stay in the Neuro Intensive Care Unit after craniotomy

    Time frame: From enrollment to transfer out of the ICU or 90 days, whichever is sooner.

  2. Intracranial hemorrhage (ICH) incidence

    Rate of intracranial hemorrhage requiring return to the operating room

    Time frame: From enrollment to hospital discharge

  3. Patient-Reported Outcome Measurement Information System-10 (PROMIS10) score

    PROMIS10 responses collected at routine postoperative neurosurgery clinic follow-up visits. The PROMIS Global 10 uses T-scores to interpret results. T-scores are standardized scores with a mean of 50 and a standard deviation of 10.

    Time frame: From enrollment to 90 days following enrollment

  4. Functional Assessment of Cancer Therapy - Brain (FACT-Br) score

    FACT-Br responses collected at routine postoperative neurosurgery clinic follow-up visits. This scale is measured on a 5 point Likert-type scale, with higher scores indicating better quality of life.

    Time frame: From enrollment to 90 days following enrollment.

  5. Composite of adverse end-organ hypoperfusion events related to antihypertensive use

    Composite measure of inpatient mortality, acute kidney injury, BNP elevation, and myocardial infarction during hospital stay.

    Time frame: From enrollment to hospital discharge or 90 days, whichever is sooner.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.

Access criteria: Data will be made accessible to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2025
First posted
Jul 30, 2025
StartActual
Apr 15, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Sep 2028
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093151
Responsible party
Patrick Kelly (Principal Investigator, Assistant Professor of Neurological Surgery, Vanderbilt University Medical Center) — Principal investigator
First posted
Jul 30, 2025
Start date
Apr 15, 2026
Primary completion
Jun 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Apr 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion